Aurinia Pharmaceuticals ( ($AUPH) ) has issued an update. Aurinia Pharmaceuticals reported a significant increase in financial performance for the ...

Aurinia (AUPH) delivered earnings and revenue surprises of +43.75% and +7.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals Inc. AUPH) on Tuesday reported third-quarter earnings of $31.6 million. On a per-share basis, the Edmonton, Alberta-based company said it had profit of 23 cents.

An update from Aurinia Pharmaceuticals ( ($AUPH) ) is now available. Aurinia Pharmaceuticals reported significant financial growth for the third ...

George Tidmarsh, the newly installed director of the FDA’s Center for Drug Evaluation and Research, was placed on leave ...

Aurinia Pharmaceuticals has strong Lupkynis sales, robust pipeline, and financial health drive growth. See why we rate AUPH ...

A lawsuit filed against George Tidmarsh, who resigned from a top FDA post on Sunday, includes a series of incendiary texts ...

Dr. George Tidmarsh, the FDA drug regulator who was placed on leave and complained of a “toxic” work environment in an ...

The director of the U.S. Food and Drug Administration's Center for Drug Evaluation and Research, George Tidmarsh, resigned on ...

Dr. George Tidmarsh had been placed on leave Friday after Health and Human Services officials were notified of the issues, a ...

Observers characterized the dismissals, policy reversals, and controversies at the FDA as a soap opera, total disarray, and potentially, unprincipled ...

The resignation of the FDA's head drug regulator George Tidmarsh comes amid concerns about conduct related to lupus nephritis drug Lupkynis.